9 Companies Advance GalNAc Technology for Precision Therapeutics
A market research report identifies nine companies developing GalNAc delivery technology to advance precision therapeutics through 2030.
ResearchAndMarkets.com has released an analysis of nine companies advancing GalNAc delivery technology for the development of precision therapeutics. The report focuses on companies that develop and utilize GalNAc conjugation to enhance the targeted delivery of nucleic acid-based medicines.
Companies highlighted in the report include Alnylam Pharmaceuticals, recognized for its RNAi-based therapies; Novartis AG, leveraging its pharmaceutical expertise; Ionis Pharmaceuticals, focusing on antisense oligonucleotide design; and Arrowhead Pharmaceuticals, combining ligand architectures with RNAi modalities.
Additional firms featured are Dicerna Pharmaceuticals, employing GalNAc techniques for hepatic indications; Silence Therapeutics, with a focus on liver-targeted delivery; Akcea Therapeutics, specializing in rare and metabolic diseases; Sirnaomics, possessing a dual-platform approach; and Aligos Therapeutics, developing GalNAc-modified nucleic acid drugs.
These companies aim to improve drug delivery to target cells, increasing therapeutic efficacy while minimizing side effects. GalNAc technology is expected to play a significant role in advancing precision medicine, particularly in treating liver and genetic diseases in the coming years.